NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

Compare
29.67 +0.23 (+0.78%)
At close: October 16 at 4:00 PM EDT
29.76 +0.09 (+0.30%)
After hours: October 16 at 7:59 PM EDT
Loading Chart for PFE
DELL
  • Previous Close 29.44
  • Open 29.50
  • Bid 29.70 x 1800
  • Ask 29.73 x 3100
  • Day's Range 29.43 - 29.82
  • 52 Week Range 25.20 - 31.54
  • Volume 19,501,742
  • Avg. Volume 31,663,284
  • Market Cap (intraday) 168.131B
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) --
  • EPS (TTM) -0.46
  • Earnings Date Oct 29, 2024
  • Forward Dividend & Yield 1.68 (5.71%)
  • Ex-Dividend Date Nov 8, 2024
  • 1y Target Est 33.25

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

88,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PFE

View More

Related Videos: PFE

This is the 3-point checklist for healthcare earnings: Strategist

Major healthcare companies, including Johnson & Johnson (JNJ) and UnitedHealth Group (UNH), reported their third quarter earnings on Tuesday morning. Mizuho healthcare equity strategist Jared Holz joins Catalysts to discuss his outlook on the healthcare sector for this earnings season. Holz identifies three key factors impacting healthcare earnings: healthcare utilization, the upcoming US presidential election, and Mergers and Acquisitions (M&A) activity. According to Holz, healthcare utilization is "the driving factor" for companies reporting earnings. Based on reports so far, he notes that the procedural earnings backdrop remains strong, "indicating a lot more patient mobility," surgeries, and other activities, which bodes well for the overall healthcare sector. "We kind of look at the sector in its entirety; it's really based so much on what patients are doing, what sort of procedures they're having, and we're finding that they're running still very strong," Holz explains. While Holz acknowledges that the presidential election will have a short-term impact on the healthcare sector, he points out that investors are closely watching the outcome. He notes that Medicare rates are typically more favorable under Republican leadership than Democratic leadership. "If that winds up being the case," he suggests, healthcare stocks could see a rebound. However, Holz doesn't anticipate significant long-term changes in the sector due to election results. Regarding M&A activity, Holz observes, "All of the pharma companies are subject to the same macro challenges across the board, which is to say that these assets in the pharmaceutical industry are not durable, and they have to continuously do M&A to keep revenue growth going and earnings growth going." To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Angel Smith

Performance Overview: PFE

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PFE
7.68%
S&P 500
22.49%

1-Year Return

PFE
2.15%
S&P 500
35.00%

3-Year Return

PFE
18.64%
S&P 500
30.66%

5-Year Return

PFE
5.52%
S&P 500
95.03%

Compare To: PFE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PFE

View More

Valuation Measures

Annual
As of 10/15/2024
  • Market Cap

    166.83B

  • Enterprise Value

    228.40B

  • Trailing P/E

    --

  • Forward P/E

    10.52

  • PEG Ratio (5yr expected)

    0.22

  • Price/Sales (ttm)

    3.02

  • Price/Book (mrq)

    1.90

  • Enterprise Value/Revenue

    4.14

  • Enterprise Value/EBITDA

    41.64

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.70%

  • Return on Assets (ttm)

    0.94%

  • Return on Equity (ttm)

    -2.74%

  • Revenue (ttm)

    55.17B

  • Net Income Avi to Common (ttm)

    -2.59B

  • Diluted EPS (ttm)

    -0.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.1B

  • Total Debt/Equity (mrq)

    79.41%

  • Levered Free Cash Flow (ttm)

    3.44B

Research Analysis: PFE

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 13.28B
Earnings 41M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

27.00
33.25 Average
29.67 Current
45.00 High
 

Company Insights: PFE

Research Reports: PFE

View More
  • Pfizer's Diverse Portfolio of Drugs and Vaccines Supports a Wide Moat

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

    Rating
    Price Target
     
  • Large Cap US Pick List - October 2024

    This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

     
  • Pfizer's Diverse Portfolio of Drugs and Vaccines Supports a Wide Moat

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

    Rating
    Price Target
     
  • Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

    In this edition, new wave of GLP-1 anti-obesity drugs may tilt the scales; US refiners' margins fading but valuations remain high; Boeing machinists union strike is unfortunate Blow; and Moderna, China Suntien Green Energy, and Mastercard.

     

Top Analysts: PFE

View More

Overall Score

Cantor Fitzgerald 47/100
Latest Rating
Overweight
 

Direction Score

BMO Capital 42/100
Latest Rating
Outperform
 

Price Score

Truist Securities 100/100
Latest Rating
Buy
 

People Also Watch